Skip to main content

Advertisement

ADVERTISEMENT

Commentary

Commentary
01/09/2019
In this expert commentary, Peter Pitts, former associate commissioner of the FDA and president of the Center for Medicine in the Public Interest, examines the implications of recent 2019 drug price increases.
In this expert commentary, Peter Pitts, former associate commissioner of the FDA and president of the Center for Medicine in the Public Interest, examines the implications of recent 2019 drug price increases.
In this expert commentary, Peter...
01/09/2019
First Report Managed Care
Commentary
12/07/2018
We asked experts about Amazon in 2017, but so much has happened since. First Report Managed Care recently sought their updated analysis on the heels of the tech giant’s recent moves.
We asked experts about Amazon in 2017, but so much has happened since. First Report Managed Care recently sought their updated analysis on the heels of the tech giant’s recent moves.
We asked experts about Amazon in...
12/07/2018
First Report Managed Care

Advertisement

Commentary
10/26/2018
Competition within a new class of drugs often leads to a balance between plan coverage and coverage requirements benefiting patients, payers, and manufacturers; so, I wanted to provide an overview of the class landscape today.
Competition within a new class of drugs often leads to a balance between plan coverage and coverage requirements benefiting patients, payers, and manufacturers; so, I wanted to provide an overview of the class landscape today.
Competition within a new class...
10/26/2018
First Report Managed Care
Commentary
09/27/2018
A recent Centers for Medicare & Medicaid Services (CMS) announcement has seemingly come and gone without the amount of discussion I thought we would see when I first heard about it.
A recent Centers for Medicare & Medicaid Services (CMS) announcement has seemingly come and gone without the amount of discussion I thought we would see when I first heard about it.
A recent Centers for Medicare &...
09/27/2018
First Report Managed Care
Commentary
09/21/2018
Although no other health system in the world is perfect, I believe reviewing the coverage of drugs within the context of their overall economic value is a strength other health systems have shown to be effective.
Although no other health system in the world is perfect, I believe reviewing the coverage of drugs within the context of their overall economic value is a strength other health systems have shown to be effective.
Although no other health system...
09/21/2018
First Report Managed Care

Advertisement

Commentary
07/27/2018
Increasing access to medications without a prescription, when properly done, has the potential to positively impact many interested parties.
Increasing access to medications without a prescription, when properly done, has the potential to positively impact many interested parties.
Increasing access to medications...
07/27/2018
First Report Managed Care
Commentary
07/06/2018
From a managed care and budget perspective, I think the release and pricing of Aimovig sets a positive stage for this class of medications.
From a managed care and budget perspective, I think the release and pricing of Aimovig sets a positive stage for this class of medications.
From a managed care and budget...
07/06/2018
First Report Managed Care
Commentary
06/22/2018
I am encouraged to see these and many other innovative strategies coming from so many organizations and government bodies nationwide.
I am encouraged to see these and many other innovative strategies coming from so many organizations and government bodies nationwide.
I am encouraged to see these and...
06/22/2018
First Report Managed Care

Advertisement

Commentary
06/01/2018
In his recent blog post, Russ J Spjut discusses the importance of balancing the need to provide value on a population scale while not forgetting the individual patient perspective.
In his recent blog post, Russ J Spjut discusses the importance of balancing the need to provide value on a population scale while not forgetting the individual patient perspective.
In his recent blog post, Russ J...
06/01/2018
First Report Managed Care
Commentary
05/23/2018
In his latest blog, Russ J Spjut, PharmD, discusses how the promise of PCSK9 inhibitors has been overshadowed by cost-effectiveness concerns among managed care professionals.
In his latest blog, Russ J Spjut, PharmD, discusses how the promise of PCSK9 inhibitors has been overshadowed by cost-effectiveness concerns among managed care professionals.
In his latest blog, Russ J...
05/23/2018
First Report Managed Care

Advertisement